/
At Elutia, our mission is to humanize medicine so that patients can thrive without compromise. We develop proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications.
The business is unprofitable at the operating level (-218.91% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 15.0% YoY. Margins deteriorated 6.6pp alongside, both lines moving the wrong way.
Negative free cash flow of -$47M. The business is consuming cash, not generating it. Operating margin contracted 6.6pp YoY, cost discipline may be slipping.
Profitability & Returns
Revenue (TTM)
$12M
▼ -15.0% YoY
Net Income (TTM)
$50M
▲ +198.9% YoY
Op. Margin
-212.60%
▼ -6.6pp YoY
ROIC
-67.85%
▲ +24.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$46M
▼ -100.3% YoY
Op. Cash Flow (TTM)
-$44M
▼ -97.8% YoY
Net Debt
-$25M
Net Cash Position
Cash & Equiv.
$28M
5Y CAGR: -22.0%
Continue Research